Global Coronary Stents (Bare Metal, Drug-Eluting,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
184
Global Coronary Stents (Bare Metal, Drug-Eluting, Bioresorable) Market 2016-2021 - Bioresorbable Stents as the Future

Dublin, Feb. 20, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Coronary Stents Market (Bare Metal, Drug-Eluting, Bioresorable): Analysis By Segment, By Region, By Country (2016-2021)" report to their offering. Global Coronary Stents Market is forecasted to grow at a CAGR of 3.05% during 2016-2021F, on account of rising incidences of cardiovascular diseases globally leading to growing number of stent procedures.

Rising development of bioresorbable stents combined with the growing awareness towards cardiovascular risks in developing countries has resulted in the growth of coronary stents market. Cardiovascular diseases are witnessing growth on account of the rise in the lifestyle related diseases including obesity, diabetes, hypertension etc. Among the types of coronary stents, market is expected to be driven by bioresorbable stents, mainly in the polylactic acid material. However, drug eluting stents will continue to generate major revenue while bare metal stents will further continue to decline. While developed regions will continue to dominate the market in terms of revenue, emerging nations are expected to respond to the market optimistically due to the developing healthcare infrastructure and rising focus on healthcare among the growing middle class population. Scope of the Report The report provides Segmentation by Stent Type: - Bare Metal stents - Drug-Eluting Stents - Bioresorbable Stents Key Topics Covered: 1. Research Methodology 2. Executive Summary

3. Strategic Recommendations 3.1. Bioresorbable Stents as the Future Market 3.2. Focus on Lowering of ASP in Coronary Stents 3.3. Opportunities in APAC Region 4. Global Coronary Stents Market: An Analysis 4.1. Product Overview 4.2. Global Coronary Stents Market 4.3. Global Coronary Stent Market, By Segments 4.4. Global Bare Metal Stents, By Value 4.5. Global Drug Eluting Stents, By Value 4.6. Global Bioresorbable Stents Market, By Segments 4.7. Global Coronary Stent Market, By Region 4.8. Coronary Stents: Pipeline Analysis 5. North America Coronary Stent Market: An Analysis 6. Europe Coronary Stent Market: An Analysis 7. APAC Coronary Stent Market: An Analysis 8. ROW Coronary Stent Market: An Analysis 9. Market Dynamics 9.1. Trends 9.2. Drivers 9.3. Challenges 10. Pricing Structure 11. Policy and Regulatory Landscape 12. M&A and Licensing Route to Coronary Stent Market 13. SWOT Analysis 14. Porter's Five Forces Model 15. Product Benchmarking 16. Company Profiles 16.1 Terumo Corporation 16.2 Boston Scientific 16.3 Stentys SA 16.4 MicroPort Scientific Corporation 16.5. Biotronik 16.6 Elixir Medical Corporation 16.7 Biosensors Inc. 16.8 Medtronic 16.9 Abbott Laboratories 16.10 Kyoto Medical Planning For more information about this report visit http://www.researchandmarkets.com/research/x2...l_coronary

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Stents

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

OnTime's Bold Vision: Transforming Home Healthcare Admin

Updated Category News Views 7

Changing the Game for Home Healthcare Every now and then, an idea rolls in that speaks to a real need, and OnTime's push to soften the burdens of the home healthcare industry might just be one of those. Built from grassroots experience, they're dropping efforts to modernize the back-end monotony so healthcare workers can zero in on, well, healthcare. A Nose-Dive into...

Continue Reading
Image Analysis Group Unveils DYNAMIKA V.7 for Clinical Trials

Updated Category News Views 185

Introduction to DYNAMIKA V.7 by Image Analysis Group Image Analysis Group (IAG) has recently launched DYNAMIKA V.7, an advanced cloud platform tailored for clinical trial imaging. Following stringent audits and certifications, including SOC II Type I compliance and British Standards Institute (BSI) surveillance audit certification, this platform stands out in its field....

Continue Reading
Sanofi's Strategic Move to Enhance Adult Vaccination Pipeline

Updated Category News Views 95

Sanofi Strengthens Its Vaccination Portfolio Sanofi SA (NASDAQ: SNY) has made a significant step in the healthcare sector by acquiring Dynavax Technologies Corporation (NASDAQ: DVAX) for approximately $2.2 billion. This acquisition, which involves a cash purchase price of $15.50 per share, signals Sanofi's commitment to enhancing its capabilities in the adult immunization...

Continue Reading
Miral Impact Fund: A New Era for Community and Environment

Updated Category News Views 135

Introducing the Miral Impact Fund Miral has taken a significant step towards environmental stewardship and social responsibility by launching the Miral Impact Fund. This initiative, launched in partnership with the Authority of Social Contribution – Ma'an, aims to create a positive impact within communities by addressing pressing social issues while promoting...

Continue Reading
Class Action Update for Regeneron Pharmaceuticals Investors

Updated Category News Views 125

Class Action Lawsuit Overview for Regeneron Pharmaceuticals Levi & Korsinsky, LLP has announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) investors should take note of a pending class action lawsuit concerning alleged securities fraud. Understanding the Class Action The lawsuit aims to recover losses for investors adversely affected by claims of fraud that...

Continue Reading